Increased Serum Pentraxin 3 in Patients with Systemic Sclerosis

Objective. To determine serum concentrations of: pentraxin 3 (PTX3) and its clinical associations in patients with systemic sclerosis (SSc). Methods. Serum PTX3 levels from 45 patients with diffuse cutaneous SSc (dSSc), 46 with limited cutaneous SSC (ISSc), and 20 healthy controls were examined by ELISA. PTX3 expression in the sclerotic skin from SSc patients was evaluated immunohistochemically. Normal and SSc fibroblasts were Cultured and PTX3 levels in the culture medium were also examined by ELISA. Results. Serum PTX3 levels were elevated in patients with SSc relative to controls. PTX3 levels in dSSc patients were significantly higher than in controls and ISSc patients. PTX3 expression in the sclerotic skin from SSc patients was more intense relative to normal skin. Elevation of serum PTX3 levels was associated with more frequent presence of pulmonary fibrosis, cardiac disease, and pitting scar/ulcer and increased serum immunoglobulin levels and erythrocyte sedimentation rates. PTX3 levels correlated positively with modified Rodnan total skin thickness score, and negatively with percentage vital capacity and percentage DLCO in patients with SSc. PTX3 levels also correlated positively with serum levels of 8-isoprostane, a marker of oxidative stress, and hyaluronan, recently identified as ail endogenous ligand for Toll-like receptors. PTX3 production from cultured SSc fibroblasts was increased by stimulation with hyaluronan. Conclusion. These results suggest that elevated serum PTX3 levels are associated with the disease severity of SSC. (First Release March 1 2009; J Rheumatol 2009;36:976-83; doi: 10.3899/jrheum.080343)